Antibiotice starts exporting to Brazil

Drugmaker Antibiotice Iasi targets approximately 14% higher sales for next year ($42 million), following the rise in exports and the new product releases on the domestic market. “We will see export growth as a result of patenting and selling the existing products on new markets; as for domestic growth, we are preparing the release of 5 or 6 new drugs. We therefore aim to post $2 million growth both for exports and for the sales on the domestic market,” Ioan Nani, Antibiotice general manager, told Ziarul Financiar. The financial problems in the Romanian health care system have prompted Antibiotice to apply a strategy intended to boost the share of exports in its total turnover over the last few years. The company secured approval to sell some of its products in the US, opened an office in Moscow and will open another one in Brazil next year. The contracts concluded with local companies to represent its interests have resulted in Antibiotice selling its products in China, India, Australia, Malaysia and Indonesia, too. ZF